Colorectal Cancers

Advances in the Management of Colorectal Cancer: Recent Evidence and Emerging Treatment Paradigms

John Strickler, MD
ctDNA-Guided Surveillance in Non-Operative Rectal Cancer

Colleen Ashley Donahue, MD
The Role of ctDNA-MRD Assessment in the Management of Colon Cancer

John Strickler, MD
Emerging Treatment Landscape for BRAF V600E Mutated Colon Cancer

John Strickler, MD
MRD and NGS Testing for Stage I-III Colorectal Cancer: Practice Changing Data in 2025

John Strickler, MD
MRD Testing for Colon Cancer: Do’s and Don’ts with a Positive Result

John Strickler, MD
MRD Testing to Guide Adjuvant Chemotherapy for Resected Colon Cancer

John Strickler, MD
MRD Surveillance for Locally Advanced Rectal Cancer

John Strickler, MD
Impact of ctDNA Testing on Survival: Can MRD Testing Make a Difference for Metastatic CRC

John Strickler, MD
Key Advances in the Management of Colorectal Cancer – The Role of Molecular Residual Disease (MRD) Assessment

Tanios S. Bekaii-Saab, MD
$Management of Chemotherapy Refractory CRC –Where the Art of Medicine Meets the Science$

Management of Chemotherapy Refractory CRC –Where the Art of Medicine Meets the Science

John Strickler, MD
Update on ctDNA in Management of Colon Cancer

John Strickler, MD